BioMark: 2025 Achievements & 2026 Vision

About this update from Biomark Diagnostics, Inc.

Celebrating A Year of Extraordinary Achievement Vancouver, British Columbia--(Newsfile Corp. - December 31, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark" or the "Company"), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its Chief Executive Officer and Founder, Rashid Ahmed Bux. Dear BioMark Shareholders and Team, As we reflect on 2025, we celebrate a transformative year that positions BioMark as the leader in early cancer detection and precision diagnostics. What we've accomplished together represents not just scientific breakthroughs—it represents the resilience, dedication, and unwavering commitment of our team to a mission that saves lives. Key Achievements 2025 Team & Capacity Regulatory & Clinical Validation Scientific Leadership & Recognition Strategic Funding & Partnerships What This Means for Our Stakeholders For Our Team You are part of an internationally recognized leader in early cancer detection. Your work directly impacts patient outcomes. Our team expansion reflects confidence in our mission-we hire the best because our science demands excellence. You are changing cancer detection. For Our Shareholders 2026 Catalysts Regulatory & Market Access IP & Competitive Positioning Clinical Data & Publications Commercial Expansion Business Scaling Outreach Revenue & Coverage Our Culture: A Message of Resilience To every member of the BioMark family—from lab scientists to business development, clinical operations, regulatory affairs, and leadership - thank you. This year tested us. We navigated regulatory complexity. We managed ambitious timelines. We scaled operations while maintaining scientific rigor. We faced skepticism and answered with data. And we never backed down. That spirit - that refusal to accept "no" as final, that commitment to excellence even when the path is uncertain—that is BioMark's culture. That is what makes us different. We Are Defined By The investors who backed us, the patients who entrusted us with their samples, the healthcare collaborators who partnered with us - they did so because they saw a team that delivers. In 2026, we will expand that impact. We build upon the achievements of 2025. Together, we will establish BioMa...

View stock analysis, news, and events for Biomark Diagnostics, Inc.